Premium
A preliminary report on a new perspective in clinical radiation sensitization and hypoxic cell chemotherapy
Author(s) -
Sealy Rossall,
Korrubel Jan,
Cridland Stephen,
Blekkenhorst Gerry
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19841015)54:8<1535::aid-cncr2820540811>3.0.co;2-f
Subject(s) - misonidazole , medicine , melanoma , radiation therapy , drug , chemotherapy , sensitization , cancer research , cancer , oncology , pharmacology , immunology , in vitro , biochemistry , chemistry
The actions of misonidazole as a radiation sensitizer, hypoxic cytotoxic, and metabolic inhibitor are all concentration‐dependent, and the commonly prescribed oral dose (I2 g/m 2 ) appears to be inadequate. The drug has, therefore, been given interstitially in solid form, when local tissue doses of the order of tens of millimolar are attained, to four patients, all with advanced disease. In the three cases (two squamous carcinomas and a malignant melanoma) in whom the drug concentration was considered to be adequate, a beneficial effect was obtained, which, in two instances, was associated with doses of radiation of 6 and 8 Gy, respectively. This approach has a wide potential application in cancer therapy.